Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 10/2019

01-10-2019 | Glioma | Research article

Seven genes for the prognostic prediction in patients with glioma

Authors: G.-H. Zhang, Q.-Y. Zhong, X.-X. Gou, E.-X. Fan, Y. Shuai, M.-N. Wu, G.-J. Yue

Published in: Clinical and Translational Oncology | Issue 10/2019

Login to get access

Abstract

Purpose

Glioma is a common malignant tumor of the central nervous system, which is characterized by a low cure rate, high morbidity, and high recurrence rate. Consequently, it is imperative to explore some indicators for prognostic prediction in glioma.

Methods

We obtained glioma data from The Cancer Genome Atlas (TCGA). Differentially expressed genes (DEGs) were obtained by R software from TCGA data sets. Through Cox regression analysis, risk scores were obtained to assess the weighted gene-expression levels, which could predict the prognosis of patients with glioma. The validity and the prognostic value of this model in glioma were confirmed by the manifestation of receiver-operating characteristic (ROC) curves, area under the curve (AUC), and 5-year overall survival (OS).

Results

In total, 920 DEGs of transcriptome genes in glioma were extracted from the TCGA database. We identified a novel seven-gene signature associated with glioma. Among them, AL118505.1 and SMOC1 were positively related to the 5-year OS of patients with glioma, showing a better prognosis for glioma; however, RAB42, SHOX2, IGFBP2, HIST1H3G, and IGF2BP3 were negatively related to 5-year OS, displaying a worse prognosis. In addition, according to risk scores, AL118505.1 was also a protective factor, while others were risk factors. Furthermore, the expression levels of SHOX2, IGFBP2, and IGF2BP3 were significantly positively correlated with glioma grades. Receiver-operating characteristic (ROC) curve assessed the accuracy and sensitivity of the gene signature. Each of the seven genes for patients with the distribution of the risk score was presented in the heat map.

Conclusion

We identified a novel seven-gene signature in patients with glioma, which could be used as a predictor for the prognosis of patients with glioma in the future.
Literature
1.
Li B, et al. The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression. PLoS One. 2011;6:e25631.CrossRef
2.
Brandes AA, et al. Temozolomide as a second line systemic regimen in recurrent high—grade glioma a phase II study. Ann Oncol. 2001;129:255.CrossRef
3.
Khasraw M, et al. Antiangiogenic therapy for high-grade glioma. Cochrane Datab Syst Rev. 2014;9:CD008218.
4.
Omar AI. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma. J Vis Exp. 2014;92:e51638.
5.
6.
Louis DN, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–20.CrossRefPubMed
7.
Turkalp, et al. IDH mutation in glioma: new insights and promises for the future. JAMA Neurol. 2014;71:1319–25.CrossRefPubMed
8.
Akagi Y, et al. Reclassification of 400 consecutive glioma cases based on the revised 2016 WHO classification. Brain Tumor Pathol. 2018;35:81–9.CrossRefPubMed
9.
Zacher A, et al. Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene. Panel Brain Pathol. 2017;27:146–59.CrossRefPubMed
10.
Li B, et al. CD133 in brain tumor: the prognostic factor. Oncotarget. 2017;8:11144–59.PubMed
11.
Lu G, et al. Phospholipase C Beta 1: a candidate signature gene for proneural subtype high-grade. Glioma Mol Neurobiol. 2016;53:6511–25.CrossRefPubMed
12.
Song WS, et al. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. J Chin Med Assoc. 2016;79:538–45.CrossRefPubMed
13.
14.
Mancini C, et al. A fetal case of microphthalmia and limb anomalies with abnormal neuronal migration associated with SMOC1 biallelic variants. Eur J Med Genet. 2018;S1769–7212:30397–8.
15.
Blaschke RJ, et al. SHOT, a SHOX-related homeobox gene, is implicated in craniofacial, brain, heart, and limb development. Proc Natl Acad Sci USA. 1998;95:2406–11.CrossRefPubMedPubMedCentral
16.
Clement-Jones M, et al. The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet. 2000;9:695–702.CrossRefPubMed
17.
18.
Dietrich D, et al. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome innon-small-cell lung cancer patients. Diagn Mol Pathol. 2012;21:93–104.CrossRefPubMed
19.
Yang T, et al. Elevated SHOX2 expression is associated with tumor recurrence of hepatocellular carcinoma. Ann Surg Oncol. 2013;20:S644–9.CrossRefPubMed
20.
Hong S, et al. SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells. Neoplasia. 2014;16:e1–5.CrossRef
21.
22.
Wang H, et al. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol. 2006;19:1149–56.CrossRefPubMed
23.
Wang Y, et al. IGFBP2 enhances adipogenic differentiation potentials of mesenchymal stem cells from Wharton’s jelly of the umbilical cord via JNK and Akt signaling pathways. PLoS One. 2017;12:e0184182.CrossRefPubMedPubMedCentral
24.
Shynlova O, et al. Insulin-like growth factors and their binding proteins define specific phases of myometrial differentiation during pregnancy in the rat. Biol Reprod. 2007;76:571–8.CrossRefPubMed
25.
Villani RM, et al. Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting Igfbp2 activity. Cancer Prev Res (Phila). 2010;3:1222–34.CrossRef
26.
Cen WN, et al. The expression and biological information analysis of miR-375-3p in head and neck squamous cell carcinoma based on 1825 samples from GEO, TCGA, and peer-reviewed publications. Pathol Res Pract. 2018;214:1835–47.CrossRefPubMed
27.
Castel D, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 2015;130:815–27.CrossRefPubMedPubMedCentral
28.
Metadata
Title
Seven genes for the prognostic prediction in patients with glioma
Authors
G.-H. Zhang
Q.-Y. Zhong
X.-X. Gou
E.-X. Fan
Y. Shuai
M.-N. Wu
G.-J. Yue
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 10/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02057-3

Other articles of this Issue 10/2019

Clinical and Translational Oncology 10/2019 Go to the issue

Research Article

Multiple sclerosis outcomes after cancer immunotherapy

Research Article

Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis

Research Article

Mitotic rate as an important prognostic factor in cutaneous malignant melanoma

Research Article

Results of a nationwide survey on multidisciplinary teams on thyroid cancer in Spain

Brief Research Article

ΔNp73 status in peritoneal and ovarian dissemination of appendicular adenocarcinoids (goblet cells)

Research Article

The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits